



## For Immediate Release

### **DATATRAK International, Inc. Forms Strategic Partnership with Inclinx, Inc.**

(April 30, 2009) Wilmington, North Carolina, USA – Inclinx, Inc. has announced today that it has entered into a strategic partnership with DATATRAK International, Inc. (NASDAQ: DATA) to offer the most comprehensive enrollment services available to pharmaceutical, biotechnology and medical device companies globally.

This partnership will enable Inclinx to leverage DATATRAK's eClinical™ platform to enhance its services as a premiere enrollment Contract Research Organization (CRO). This alliance offers the first ever enrollment solution that delivers seamless integration and execution of services, reducing a Sponsor's need to outsource to multiple vendors for successful trial completion. Access to data is powerful for efficient and dynamic enrollment execution; therefore, this partnership immediately benefits both Inclinx and DATATRAK clients.

"Inclinx will be the enrollment CRO offering DATATRAK's eClinical™ solutions. With EDC services repeatedly becoming a request of our customers, this partnership has been in our corporate vision for quite some time. We are ecstatic that DATATRAK has entered into this strategic partnership with Inclinx," says J. Tobin Geatz, President and CEO, Inclinx. "DATATRAK's focus on ease of use and integration is a great fit into the enrollment solutions already provided by Inclinx. As a forward-looking CRO, we are continuously developing our services to improve clinical development timelines. This partnership will undoubtedly provide immediate data-driven, results-oriented solutions for our clients."

"Inclinx brings a unique skill set to our CRO Connect Program. As a CRO specializing in enrollment solutions, Inclinx's technologies and services complement DATATRAK's already comprehensive eClinical platform," said DATATRAK's CEO Laurence P. Birch. "We are pleased to support Inclinx as they expand their service offering."

DATATRAK's CRO Connect Program is a collaborative initiative with CROs that offers the benefits of our comprehensive DATATRAK eClinical™ solution through an innovative Enterprise Transfer program. This program allows CROs to package their services around our eClinical platform in order to gain efficiencies and increased market share. The CRO Connect Program's flexible pricing and specialized consulting and professional services provides participants with the tools necessary to realize new growth opportunities.

### **About DATATRAK International, Inc.**

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and



ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. The DATATRAK eClinical™ software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at [www.datatrak.net](http://www.datatrak.net).

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; delisting of the Company's common shares from the Nasdaq Capital Market; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

### **About Inclinx**

Inclinx, Inc. is a global enrollment Contract Research Organization (CRO) specializing in customized Phase I-IV clinical trial enrollment solutions. Inclinx services deliver productive investigative sites and qualified patients for Sponsors, resulting in successfully completed



clinical trials for the pharmaceutical, biotech and medical device industries. Inclinix's clients benefit from leading edge technologies including Critical Population Research® and InSite VMR™ which serve as the foundation for protocol and enrollment feasibility. Comprehensive enrollment solutions include site recruitment, patient recruitment, clinical and medical marketing communications, patient compliance and education, and the InSite Screener™ and InSite Patient Tracker™ for comprehensive patient qualification and retention. Since 1999, Inclinix (formerly PharmaTech Solutions, Inc.) has participated in over 400 clinical trials in over 130 indications. Inclinix corporate headquarters is located in Wilmington, North Carolina with additional offices in Annapolis, Maryland and Gothenburg, Sweden. For more information please visit: [www.inclinix.com](http://www.inclinix.com).

**INCLINIX CONTACT:** Kristin Sacre, Director, Corporate Marketing  
Inclinix, Inc. +1-910-332-2682 or [ksacre@inclinix.com](mailto:ksacre@inclinix.com)

**DATATRAK CONTACT:** Raymond J. Merk, Chief Financial Officer and Chief Operating Officer, DATATRAK International, Inc., +1-440-443-0082 x181